High-dose omalizumab use in patients with chronic spontaneous urticaria
- 1 April 2020
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (4) , 1426-1427.e1
Abstract
No abstract availableFunding Information
- Novartis
This publication has 8 references indexed in Scilit:
- Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticariaJournal of Allergy and Clinical Immunology, 2018
- Omalizumab in chronic spontaneous urticariaAnnals of Allergy, Asthma & Immunology, 2018
- Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria PatientsInternational Archives of Allergy and Immunology, 2018
- The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- Responsiveness and minimal important difference of the urticaria control testJournal of Allergy and Clinical Immunology, 2017
- The minimal important difference for measures of urticaria disease activity: Updated findingsAllergy and Asthma Proceedings, 2015
- Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria controlJournal of Allergy and Clinical Immunology, 2014
- The use of omalizumab in the treatment of severe allergic asthma: A clinical experience updateRespiratory Medicine, 2009